Latest Manufacturing Operations News

Page 1 of 8
Peak Processing has secured the maximum five-year renewal for its Oldcastle, Ontario processing and sensory licence, replacing a sequence of one-year approvals. The longer term gives the ASX-listed THC beverage manufacturer more certainty as it scales production and adds product formats.
Victor Sage
Victor Sage
11 Nov 2026
Delorean has reached Financial Close on its $62.1 million NSW1 Horsley Park bioenergy facility, activating $30.5 million of government grants and a 25-year Brickworks gas supply agreement. Procurement can now begin, with construction targeted for early 2027, although Tanarra’s debt documentation and the project’s funding mix still warrant attention.
Victor Sage
Victor Sage
9 Nov 2026
Mayne Pharma will sell its international operations, including the Salisbury manufacturing site, to Evaris Pharma for $55.5 million in cash. The deal leaves the company focused entirely on its US Women’s Health, Dermatology and DistributeRx businesses, subject to ACCC approval.
Victor Sage
Victor Sage
6 Nov 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
Yowie Group has entered FY27 with US$71,000 in cash, a 35% drop in US gross sales and a fully drawn A$4 million working capital facility. The confectionery maker is pursuing an approximately A$6 million two-tranche capital raising while its ASX quotation remains suspended.
Victor Sage
Victor Sage
29 Oct 2026
Pure Foods Tasmania reported a sharper September quarter, with customer receipts rising to A$1.22 million while operating cash outflow fell to A$311,000. The company remains cash flow negative and reliant on financing capacity, but says the figures mark progress towards a sustainable turnaround.
Victor Sage
Victor Sage
26 Oct 2026
Wide Open Agriculture has completed a study for a proposed 10,000-tonne-per-year lupin protein facility with indicative annual revenue of A$240 million to A$295 million. The project remains unfunded, unapproved and years from production, leaving contract manufacturing as the immediate test of the company’s strategy.
Victor Sage
Victor Sage
6 Oct 2026
Iperion reported a lower loss for the year ended 31 March 2026, but its cash reserves and net assets fell sharply, leaving the NZX-listed materials company reliant on related-party funding and director support. Its Pathoglaze manufacturing operation is also being moved from Malaysia to Singapore while customer trials continue.
Victor Sage
Victor Sage
30 Sept 2026
PPK Group has converted the sale of its Craig International Ballistics stake into a substantially stronger balance sheet, reporting a $19.2 million FY2026 profit and $27.7 million in cash. The challenge now is turning that one-off windfall into a durable operating business without overpaying or losing patience.
Victor Sage
Victor Sage
25 Sept 2026
EBR Systems’ new Santa Clara manufacturing facility has entered the FDA’s pre-approval inspection process, marking a key regulatory step for its wireless cardiac pacing business. The company continues to expect approval by the end of 2026, but the inspection does not yet amount to clearance.
Victor Sage
Victor Sage
15 Sept 2026
OncoSil Medical has moved closer to local production after contract manufacturer Cyclotek secured ISO 13485 certification for its quality management system. Production at the Macquarie Park facility remains targeted for the end of 2Q FY27, subject to further regulatory approval.
Victor Sage
Victor Sage
9 Sept 2026

Browse the archive

Full archive